Skip to main content
Premium Trial:

Request an Annual Quote

Biametrics, MorphoSys to Expand High-Throughput Antibody Screening Collaboration

Premium

German technology firm Biametrics announced this week that it would expand its relationship with MorphoSys following a successful preliminary study that paired Biametrics' microarray technology with MorphoSys' therapeutic antibodies.

Florian Pröll, managing director at Tübingen-based Biametrics, said in a statement that the company "looks forward to expanding our collaboration in the field of biomolecular interaction analysis" with MorphoSys.

Biametrics and MorphoSys have been working together in the area of high-throughput antibody screening. According to Biametrics, in a pilot study, they used Biametrics' label-free B-screen microarray platform to characterize Fab fragment antigen interactions.

Biametrics recently launched B-screen as a research tool, and a handheld instrument called B-portable that relies on the same label-free technology is set for introduction later this year.

Markus Enzelberger, senior vice president and head of discovery alliances and technologies at MorphoSys, said in a statement that MorphoSys views B-screen as a "promising technology in the field of epitope mapping."

MorphoSys is based in Martinsried, Germany. The company maintains a therapeutic pipeline of more than 80 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, and Alzheimer’s disease.

The Scan

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.

Machine Learning Improves Diagnostic Accuracy of Breast Cancer MRI, Study Shows

Combining machine learning with radiologists' interpretations further increased the diagnostic accuracy of MRIs for breast cancer, a Science Translational Medicine paper finds.

Genome Damage in Neurons Triggers Alzheimer's-Linked Inflammation

Neurons harboring increased DNA double-strand breaks activate microglia to lead to neuroinflammation like that seen in Alzheimer's disease, a new Science Advances study finds.

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.